West Pharma (WST) Reports Q3 EPS of $0.44
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
West Announces Third Quarter 2015 Results
October 29, 2015 7:01 AM EDTEXTON, PA -- (Marketwired) -- 10/29/15 -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third quarter of 2015 and updated financial guidance for the full year 2015.
Executive Summary
Third quarter 2015 reported sales of $344.5 million were 3.2% below prior-year sales. Net sales at constant currency grew by 5.2% as foreign currency translation reduced reported sales by over 8%. Gross margin improves year-over-year on growth in high-value pharmaceutical packaging sales. Third quarter reported diluted EPS was $0.02. Adjusted diluted EPS of $0.44 excludes a $0.42 non-cash pension-settlement charge. EPS comparisons to the... More